COMMUNIQUÉS West-GlobeNewswire

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
25/01/2024
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics [...]
Introducing cutting-edge features to transform the dental experience: PreVu Software unveils AI-powered enhancements for smile simulation software
25/01/2024
FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the launch of new, innovative technology that will continue our tradition of delivering [...]
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
25/01/2024
Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children [...]
Communiqué de presse : Dupixent® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois
25/01/2024
Dupixent ® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Approbation fondée sur les résultats de l’essai de phase III EoE KIDS ayant [...]
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25/01/2024
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
25/01/2024
Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of the Company and the [...]
Confluent Announces Significant Investment in ATI Nitinol Melt Expansion
25/01/2024
Confluent Becomes ATI’s Fulfillment Partner for Medical Nitinol SCOTTSDALE, Ariz., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more [...]
Renovaro Biosciences Announces Results of Special Meeting of Shareholders
25/01/2024
LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’ [...]
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25/01/2024
License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or [...]
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
25/01/2024
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial [...]
Increase of 2023 revenue at €10.5 million
25/01/2024
Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8 [...]
Hausse du Chiffres d'affaires annuel à 10,5 millions d'euros
25/01/2024
Communiqué de presse Ecully, le 25 janvier 2024 – 18h00 Chiffre d’affaires 2023 de 10,5 M€ En milliers d’euros Chiffres non audités 2023 2022 Variation 2023/2022 CA 1 er trimestre 2 399 1 342 + 79% CA 2 e trimestre 3 [...]
European Bioplastics Calls for Action to Accelerate Biopolymers Industrial Growth
25/01/2024
BRUSSELS, Belgium, Jan. 25, 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) released its Policy Manifesto today, calling on the European Union (EU) to develop a comprehensive Biopolymers Industrial Action Plan to [...]
European Bioplastics lance un appel à l'action pour accélérer la croissance industrielle des biopolymères
25/01/2024
BRUXELLES, Belgique, 25 janv. 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) a publié aujourd'hui son manifeste politique, appelant l'Union européenne (UE) à développer un plan d'action industriel complet pour les [...]
QIAGEN announces partnership with Penn State University to advance microbiome sciences
25/01/2024
Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education [...]
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
25/01/2024
Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million [...]
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
25/01/2024
Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR [...]
Wellness Redefined: Return Healthy Launches Unique Approach to Enhancing Physical, Mental, and Emotional Resilience
25/01/2024
St. George, Utah, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Return Healthy is proud to announce the launch of its new website and revolutionary approach to holistic wellness designed to help individuals enhance their physical [...]
Castellum Announces Pricing of $2.7 Million Registered Direct Offering
25/01/2024
BETHESDA, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government today announced [...]

Pages